The study focuses on Chronic recurrent multifocal osteomyelitis, a rare condition that causes recurring inflammation and pain in several bones. The investigational medication is zoledronic acid, a drug given through an IV infusion that is intended to reduce bone pain and inflammation. Children who do not get relief from standard anti‑inflammatory medicines may receive either the active drug or an inactive substance (placebo) for comparison.
The purpose of the study is to determine whether the drug improves pain levels after 12 weeks compared with placebo. Participants receive an infusion at the start of the study, then again at about 12 weeks and 24 weeks, with follow‑up visits extending to 36 weeks. At each visit, pain is recorded using simple age‑appropriate scales that involve faces or a line marked from “no pain” to “worst pain.” Whole‑body imaging with MRI (a scan that creates detailed pictures of the bones) is performed to see how many bone lesions are present. Safety checks include monitoring for flu‑like symptoms, headache, and low levels of phosphate or calcium in the blood.
France 